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Background: Many stimuli can successfully protect the heart against ischemia. We
investigated whether gap junction uncoupling before ischemia was myoprotective.
We also studied the function of the adenosine triphosphate–dependent potassium
channel, which has been implicated in the mechanism of pharmacologic precondi-
tioning, with respect to gap junction physiology.
Methods: Twenty-eight rabbit hearts were placed on a Langendorff perfusion
apparatus. Five were given a 5-minute infusion of 1 mmol/L heptanol (a gap
junction uncoupler), 5 were given 10 mol/L 2,3-butanedione monoxime (an
electromechanical uncoupler), and 6 were given no drug. The left anterior descend-
ing coronary artery was then occluded for 1 hour and reperfused for 2 hours. Six
hearts received 10 mol/L glybenclamide before heptanol to evaluate the role of the
adenosine triphosphate–dependent potassium channel. Six hearts underwent isch-
emic preconditioning with 2 cycles of 5 minutes of global ischemia and reperfusion.
Action-potential duration of the ischemic zone, left ventricular developed pressure,
and coronary flow were measured continuously. Infarct size was determined at the
end of reperfusion.
Results: Heptanol significantly reduced infarct size (from 46%  2% to 22%  5%,
P  .01), an effect that was not prevented by glybenclamide. Butanedione mon-
oxime decreased developed pressure but did not significantly reduce infarct size
(46%  5% vs 46%  2%, P  not significant). There were no differences among
groups with regard to developed pressure or action-potential duration.
Conclusion: Directly blocking gap junctions preconditions the heart. This protection
is not a direct result of a decrease in developed pressure before a prolonged ischemic
period nor is it achieved through a mechanism involving the adenosine triphosphate–
dependent potassium channel.
Short episodes of myocardial ischemia stimulate a protective defensemechanism against prolonged ischemia.1 This process has beentermed ischemic preconditioning (IPC). It has been reported that highlevels of arachidonic acid (AA), as well as linoleic and decosahex-anoic acids, are released during ischemia.2 AA has been shown touncouple gap junctions.3,4 The preconditioning effect of controlled
gap junction uncoupling before ischemia, however, is unknown. Therefore we
hypothesized that gap junction uncoupling alone confers protection against a pro-
longed ischemic insult.
In addition to ischemia, however, many other methods have been used to provoke
the preconditioning response, such as cardiopulmonary bypass,5 -adrenergic ago-
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nists,6,7 protein kinase C activators,6,8 adenosine,6,8 and
adenosine triphosphate (ATP)–sensitive potassium channel
openers.9,10 Because the ATP-dependent potassium
(KATP) channels appear to play a major role in precondi-
tioning,11-13 we attempted to dissect out their role in pre-
conditioning by using the KATP channel blocker glyben-
clamide.
Material and Methods
Animals received humane care in compliance with the “Principles
of Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory An-
imal Resources, National Research Council, and published by the
National Academy Press, revised 1996.
Adult male New Zealand rabbits, weighing between 2.8 and 3.0
kg, were anesthetized with 30 mg/kg sodium pentobarbital and
anticoagulated with 1000 units of sodium heparin through an ear
vein. Once the corneal reflex was abolished, the rabbits were
placed in the supine position, and the chest was entered through a
bilateral thoracotomy. The heart was rapidly excised and placed in
an iced bath of Krebs-Henseleit solution (Na, 135 mmol/L; K,
4.7 mmol/L; Ca, 1.7 mmol/L; P04, 1.1 mmol/L; Mg, 1.2
mmol/L; HC03, 25 mmol/L; glucose, 11.5 mmol/L; pyruvate, 4.9
mmol/L; and fumarate, 5.4 mmol/L). The aorta was instrumented
with a stainless-steel 8F cannula, and the heart was suspended
from the cannula within a heated glass chamber (Radnotti, Mon-
rovia, Calif). The aorta was then perfused with oxygenated (95%
O2/5% CO2) Krebs-Henseleit solution at 37°C and 75-mm-Hg root
pressure.
The hearts were permitted to equilibrate for 20 minutes. During
that period, both atria were excised, and a small balloon was
placed through the mitral valve into the left ventricle. Balloon
pressure was monitored continuously (Millar Corporation, Hous-
ton, Tex). The initial end-diastolic pressure was set to 5 to 10 mm
Hg by means of water inflation, and the volume was maintained
constant throughout the experiment. The hearts were paced at 150
beats/min with an asynchronous pacemaker (Medtronic, Minneap-
olis, Minn). Monophasic action potentials were recorded from the
left ventricular epicardium within the distribution of the left ante-
rior descending coronary artery (LAD) by using an 8F spring-
loaded probe (EP Technologies, Mountainview, Calif). Coronary
flow was measured directly by means of timed collection.
The overall experimental protocol is shown in Figure 1. Six
hearts served as controls without treatment before LAD ischemia.
Six hearts underwent global IPC before LAD ischemia. This was
accomplished with 2 episodes of 5 minutes of complete aortic
inflow occlusion followed by 5 minutes of reperfusion. Five hearts
received a 5-minute infusion of 1 mmol/L heptanol, a gap junction
uncoupling agent, followed by a 5-minute washout period before
LAD ischemia. To determine whether KATP channels are in-
volved in the myocardial response to gap junction uncoupling, 6
hearts received a 5-minute infusion of 10 mol/L glybenclamide
before heptanol infusion. Because gap junction uncoupling re-
sulted in decreased developed pressure during treatment, 5 hearts
were treated with 10 mmol/L 2,3-butanedione monoxime (BDM;
an electromechanical uncoupler).14
Regional ischemia was then induced by broadly encircling the
LAD close to its origin with a 3-0 silk suture and snaring with a
tourniquet. At the end of 1 hour of ischemia, reperfusion was
achieved by releasing the tourniquet and briefly massaging the
LAD with a moistened cotton swab. After reperfusion, the hearts
were removed from the perfusion apparatus, the suture was
resnared, and 2 mL of monostryl blue was infused through the
aortic cannula to stain tissue not at risk. The right ventricle was
excised, and the left ventricle was sectioned horizontally at 1- to
2-mm intervals. The slices were then incubated in 1% triphenyl
tetrazolium chloride for 15 minutes to stain viable tissue pink.
Tissue remaining unstained was therefore infarcted. Both sides of
each section were scanned (Sigma Scan; Jandel Scientific, San
Rafael, Calif) into an IBM-compatible computer (Dell Corp, Aus-
tin, Tex). Infarct size was expressed as a percentage of the area at
risk:
Infarct size 

slices
 Infarct area side A  Infarct area side BTotal area side A  Total area side B  Slice weight
 Risk area side A  Risk area side BTotal area side A  Total area side B  Slice weight
 100%
Comparisons among groups were made with analysis of vari-
ance for repeated measures (Systat v5.02; Systat, Inc, Evanston,
Figure 1. Schematic diagram of experimental protocols. Drugs were infused before 60 minutes of regional ischemia
and 120 minutes of reperfusion. GI, Global ischemia; Rep, drug-free reperfusion; Hep, 1 mmol/L heptanol; Gly, 10
mol/L glybenclamide.
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Ill). As indicated, between-group multiple comparisons were made
with the Tukey post-hoc test.
Results
Developed Pressure
End-systolic pressure and end-diastolic pressure were mea-
sured directly from the balloon pressure tracings, and peak
developed pressure (PDP) was calculated as the difference
between end-systolic pressure and end-diastolic pressure for
each beat. During the pretreatment phase, there were sig-
nificant changes (Figure 2, A). Heptanol, heptanol with
glybenclamide, and BDM all reduced PDP to a similar
degree during pretreatment (Figure 2, B). During regional
ischemia, PDP was significantly reduced in all groups.
During reperfusion, PDP returned toward control values,
with no significant differences among groups.
Action-potential Duration
Neither heptanol, glybenclamide, nor BDM had a signifi-
cant effect on action-potential duration to 50% repolariza-
Figure 2. A, Changes in developed pressure during pretreatment, regional ischemia, and reperfusion phases. Data
are given as mean  SEM. There were no significant differences between groups. B, Detail of changes in
developed pressure during the pretreatment phase only. Data are given as mean  SEM. Open triangles indicate
P values of less than .05 comparing all groups between time 5 minutes and time 10 minutes. There were no
significant differences between groups. Gly-Hep, 10 mol/L glybenclamide plus 1 mmol/L heptanol.
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tion (APD50). During pretreatment, transient ischemia sig-
nificantly reduced APD50, but during regional ischemia,
there were no significant differences among groups. During
reperfusion, APD50 was shorter in BDM hearts, but the
differences did not reach significance.
Coronary Flow
Heptanol pretreatment tended to increase coronary flow,
and this change was not attenuated by prior infusion of
glybenclamide. All hearts showed a significant decrease in
coronary flow during regional ischemia and a significant
return to control during reperfusion; there were no signifi-
cant differences among groups.
Infarct Size
There were no significant differences in area at risk, left
ventricular weight, and risk area weight among groups
(Table 1). A comparison of infarct sizes is shown in Figure
3. Control hearts had an infarct size of 46%  2%. IPC
significantly reduced infarct size to 22%  3% (P  .01).
Hearts exposed to heptanol before regional ischemia also
showed a significant decrease in infarct size (22%  5%,
P .01). Infusion of glybenclamide before heptanol did not
significantly change infarct size (25%  3%, P  not
significant compared with heptanol alone), whereas pure
electromechanical uncoupling with BDM did not precondi-
tion (46%  5%, P  not significant).
Discussion
Preconditioning has been described as a possible mecha-
nism for myocardial protection. Since the original report by
Murry and associates,1 many investigators have confirmed
that IPC reduces ventricular infarct size after prolonged
ischemia. However, as shown in several studies, IPC is not
benign: It increases end-diastolic pressure, and therefore
even a brief period of ischemia should be avoided if possi-
ble. This has caused investigators to search for a mechanism
of preconditioning that does not harm the ventricle. To date,
many different stimuli have been found to provoke a pre-
conditioning response, including -adrenergic agonists,6,7
TABLE 1. Weights of the left ventricle, area at risk, infarct area, and infarct size for all experiment groups
LV weight (g) Area at risk (g) Infarct area (g) Infarct size (%)
Control 3.34 0.19 2.50 0.29 1.17 0.15 46 2
IPC 3.13 0.19 2.11 0.14 0.46 0.08 22 3*
Heptanol 3.53 0.12 2.46 0.40 0.52 0.11 22 5*
Gly-Hep 3.58 0.12 2.15 0.14 0.66 0.11 25 3*
BDM 3.48 0.14 2.49 0.25 1.17 0.16 46 5
Data are given as mean  SEM.
LV, Left ventricular; Gly, 10 mol/L glybenclamide; Hep(tanol), 1 mmol/L heptanol.
*P  .05 with respect to control.
Figure 3. Changes in infarct size expressed as a percentage of the area at risk. Data are given as mean  SEM.
Gly-Hep, 10 mol/L Glybenclamide plus 1 mmol/L heptanol. Open triangles indicate a P value of less than .05
compared with control.
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activators of protein kinase C,6,8 adenosine,6,8 and ATP-
sensitive potassium channel openers.9,10
Pharmacologic preconditioning offers many potential ad-
vantages over IPC. Mechanical damage to the coronary
artery from local ischemic maneuvers can be avoided.
Agents can be infused, in some cases, directly into the blood
stream. Pharmacologic agents can be reversed or are me-
tabolized away quickly. The dosages can be precisely con-
trolled and individualized.
Despite these many stimuli, no comprehensive mecha-
nism of action has yet been described for preconditioning,
either ischemic or pharmacologic. Our data suggest for the
first time that gap junction uncoupling preconditions the
heart and that this protection is conferred independent of
either KATP channel activation or acute depression of
mechanical performance.
Clinical Applications
An important application for preconditioning lies in protect-
ing the arrested heart during complex operations. The cur-
rently popular myoprotective strategy of intermittently in-
fusing cold potassium-rich crystalloid or sanguine
cardioplegia results in significant mechanical and electrical
derangements in the early postoperative period. Many re-
searchers have already tried to add the beneficial effects of
pharmacologic preconditioning to potassium cardioplegia,
but the results have been mixed.15,16 Although these exper-
iments were not carried out in an arrested heart, it is rea-
sonable to expect that pretreatment with a gap junction
uncoupler will improve postcardioplegic recovery.
Role of Gap Junctions in Preconditioning
In 1991, Murry and coworkeres17 found that AA was lib-
erated during transient ischemia. Since then, investigators
have shown that AA uncouples isolated ventricular myocyte
pairs4 and that octanol, a gap junction uncoupler, protects
the brain from ischemia.18 With regard to the heart, heptanol
has been shown to limit myocardial infarct size when in-
fused after ischemia and during reperfusion.19 Although
consistent with these other studies, we have shown for the
first time that the infusion of heptanol before ischemia
protects the heart from prolonged regional ischemia.
The mechanism by which preconditioning in general
reduces infarct size remains an object of intense investiga-
tion. It is quite likely, however, that cell-to-cell communi-
cation plays an important role in this process because sec-
ondary messengers travel across gap junctions and transmit
death messengers. The mechanism underlying heptanol’s
protective effect remains unclear because it has been shown
that recovery of coupling is quite rapid once the heptanol is
washed out (ie, on the order of 90 to 120 seconds). There-
fore it is more likely that brief cellular uncoupling serves
more as a trigger event than a mechanism: A cell is better
able to uncouple itself from its sick neighbors after a pre-
treatment than it is without such a stimulus.
Role of the KATP Channel
It appears that many of the drugs proved effective at phar-
macologic preconditioning exert their effect by activating
the KATP channel. By treating the heart with glyben-
clamide to block KATP channels before heptanol infusion,
we were able to determine that the KATP channel does not
participate in heptanol’s preconditioning mechanism. We
chose a 5-minute glybenclamide infusion before heptanol
preconditioning because we have shown in other studies
that this sufficiently blocks the protective effects of the
KATP channel opener pinacidil.20,21
Study Limitations
We studied rabbit hearts in a nonworking, isolated crystal-
loid-perfused model. The drawbacks of this model include,
but are not limited to, differences in energetics and perform-
ance between working and nonworking models, as well as
problems with an asanguinous perfusate. Although a more
perfect reflection of the clinical state might have been
achieved with an in situ, blood-perfused, working heart
model, data collection, model manipulation, and drug de-
livery would have proved far more difficult.
We also chose to study global ventricular function rather
than regional function, as reflected by endocavitary pressure
development. To study regional function in such a small
heart as the rabbit’s, the state of the art would require direct
instrumentation with ultrasonographic equipment, damag-
ing the myocardium. We do not believe that this is a
significant limitation, however, because our developed pres-
sure changes were quite pronounced and easily tabulated.
Finally, there has been some controversy surrounding the
time allowed for reperfusion. In this study we used 120
minutes of reperfusion, which clearly yielded a discernable
infarct size, as measured with triphenyl tetrazolium chlo-
ride. Although investigators have used reperfusion times
varying from 60 to 180 minutes,22-27 we demonstrated, in a
separate set of experiments, that hearts subjected to 180
minutes of reperfusion exhibited a similar infarct size to
those reperfused for 120 minutes.26
Conclusion
Pretreatment of the heart with the gap junction uncoupler
heptanol protects the heart against prolonged regional isch-
emia. This mechanism is independent of both the KATP
channel and electromechanical depression.
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